Introduction word count 485
JPET # 78105

ABSTRACT
Diabetes is associated with increased risk for complications following coronary bypass grafting surgery (CABG). Augmented superoxide (
• O 2 -) production plays an important role in diabetic complications by causing vascular dysfunction. The potent vasoconstrictor endothelin-1 (ET-1) is also elevated in diabetes and following CABG.
However, the effect of ET-1 on JPET # 78105
Introduction
In addition to being a risk factor for coronary artery disease, diabetes increases the risk of post-operative vasospasm, graft stenosis and other vascular complications following coronary bypass grafting surgery (CABG) (Stewart et al., 2000) . This, in part, explains why diabetic patients suffer a high incidence of unfavorable cardiac events in the postoperative period (Cohen et al., 1998) . Adverse CABG outcomes in diabetic patients are most likely to be multifactorial but properties of bypass conduits may directly contribute to vascular dysfunction both in the acute and late phase. Excess generation of reactive oxygen species (ROS), especially
• O 2 -, can alter vascular function not only by reducing nitric (NO) bioavailability and thereby impairing the vasorelaxation response acutely, but also generating hydrogen peroxide (H 2 O 2 ) and cytotoxic peroxynitrite (ONOO -). These molecules can directly stimulate growth of vascular smooth muscle cells, which may contribute to graft stenosis (Griendling and FitzGerald, 2003b; Griendling and FitzGerald, 2003a) . ONOO -can alter function of biomolecules by protein nitration and lipid peroxidation (Turko et al., 2001) as well as causing singlestrand DNA breakage and endothelial cell apoptosis (Soriano et al., 2001 ), all of which might contribute to graft stenosis in the late phase. Guzik et al. demonstrated that enhanced
• O 2 -generation in bypass conduits of diabetic patients is mediated by NAD(P)H oxidase and uncoupled nitric oxide synthase (eNOS) (Guzik et al., 2000; Guzik et al., 2002) . However, the effect of increased
• O 2 -generation in diabetes on contractile properties of bypass conduits is not clear.
ET-1 is a potent vasoactive peptide with mitogenic properties. Elevated plasma levels of ET-1 have been reported in atherosclerosis and diabetes as well as during and JPET # 78105 5 following CABG surgery (Lerman et al., 1991) . CABG results in a biphasic increase in circulating ET-1 levels, which is associated with a complex recovery in the immediate postoperative period. Higher plasma ET-1 levels are associated with longer intensive care unit stay (Dorman et al., 2000) . Furthermore, there is a positive correlation between conduit sensitivity to ET-1 and prolonged need for vasodilator support with nitroglycerin (Bond et al., 2001 ). These observations provide evidence that increased ET-1 levels may negatively impact outcome in CABG patients. Yet, the mechanism by which ET-1 alters bypass conduit function in diabetes remains to be determined. Medium and kept on ice. Specimens were transferred to the laboratory where the surrounding fat was carefully removed. The specimens were then rinsed in sterile saline, cut into 3 mm segments and immediately snap-frozen or used in contractility experiments. To determine the effect of ET-1 on superoxide generation, vessels segments were incubated with 10 or 100 nM ET-1 for 30 min and then frozen. The patients' pre-operative co-morbidities and demographics were recorded and entered into a database (Table 1) . Medications of the control and diabetic patients were similar with the exception of the hypoglycemic agents.
Vascular reactivity. After the fat tissue was carefully removed, SV was cut into 2 to 3 mm rings and the rings were mounted at the optimal diastolic tension (2 g) in 5-ml tissue baths containing oxygenated Krebs buffer maintained at pH 7.4 and 37 o C.
Isometric contractions were recorded with digital force transducers that are integrated with a myograph data acquisition system (Danish Technologies, Denmark). After the rings were equilibrated for 1 h, rings were challenged with 70 mM KCl to assess the JPET # 78105 viability. At plateau, the integrity of endothelium was tested by 100 nM acetylcholine (Ach). In endothelium-intact vessels, the dose-response curves were generated using phenylmethylsulfonyl fluoride (PMSF), 1µg/ml aprotinin, 1µg/ml leupeptin, 1µg/ml pepstatin). The homogenate was centrifuged for 20 min at 4000 rpm and 4 ºC. The supernatant was further centrifuged in an ultracentrifuge for 45 min at 60,000 rpm (g) at 4°C. The supernatant was saved as the cytosolic fraction and the pellet was resuspended in 100 µl buffer as the particulate membrane fraction. Superoxide was measured using luminol derivative L-012, which has been recently shown to be more sensitive than lucigenin and not to undergo redox recycling (Daiber et al., 2004 is light sensitive all work with L-012 was done in the dark. The specificity of L-012 for
• O 2 -was confirmed by addition of SOD (150 U/ml), which decreased the luminescence to background levels in cell free experiments as well as in measurements with tissue homogenates.
Measurement of ET-1.
The amount of ET-1 in the plasma was determined using an enzyme-linked immunoassay kit (ELISA), specifically designed for direct measurement of plasma ET-1 (American Research Products, Belmont, MA) as we previously described (Ergul et al., 1996) .
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Results
Altered vascular reactivity of CABG conduits in diabetes.
The ability to contract and relax in response to agonist stimulation is an important determinant of the performance of CABG conduits. Since ET-1 is the most potent contractile agent and is also elevated during and after CABG surgery, we investigated the contractile response in SV conduits obtained from diabetic (n=15) and nondiabetic (n=15) patients. As shown by the data on Figure 1 and Table 2 , maximum response to ET-1 was significantly higher in the diabetic group (167 ± 9 %) than in the nondiabetic group (124 ± 7 %) without a significant difference in the sensitivity (EC 50 ) to ET-1 (48 ± 11 nM vs 43 ± 12 nM). In a subset of experiments (n=7), preincubation of bypass conduits with PEG-SOD reduced the maximum contraction to ET-1 from 167 ± 9% to 139 ± 5% and 124 ± 7% to 112 ± 3% in the diabetic and nondiabetic groups, respectively, and this was significant in the diabetic group (p<0.05). Maximum response to PE (% contraction of 70 mM KCl) was slightly higher in the diabetic group (133 ± 11 vs 112 ± 9 %) and preincubation with PEG-SOD did not affect the response.
Impaired vascular relaxation is a well-described phenomenon of endothelial dysfunction in diabetes. In order to determine whether and to what extent the dilatory response of SV conduits is blunted in diabetes, endothelium-dependent vasorelaxation was assessed using Ach. Maximum relaxation (Rmax) was significantly lower in the SV specimens obtained from diabetic patients (46% vs 70% in nondiabetic patients).
Presence of PEG-SOD significantly improved the vasorelaxation response in diabetics
This article has not been copyedited and formatted. The final version may differ from this version. were stimulated with 100 nM ET-1 for 30 min, which caused a significant increase in
• O 2 -formation in both groups (Fig. 3B ). Lower concentrations of ET-1 (10 nM) also increased DHE fluorescence by 27% in the diabetic group (data not shown).
To further investigate sources of
• O 2 -generation in bypass conduits, NAD(P)H oxidase activity in the cytosolic and membrane fractions of vascular homogenates was examined using chemiluminescent dye L-012. Basal superoxide production in the membrane fractions in nondiabetic and diabetic groups was 5,380± 940 and 16,362 ± 4,551 RLU/min.µg, respectively (Fig. 4A ). Presence of nonspecific (100 µM diphenyleneiodonium-DPI) and relatively specific (30 µM apocynin) inhibitors of In order to determine the effect of ET-1 on NAD(P)H oxidase activity, SV samples (n=5/group) were incubated with 100 nM ET-1 for 30 min and oxidase activity was then measured. As shown in Figure 4B , ET-1 had no effect on membrane NAD(P)H oxidase activity in either group. ET-1 stimulation did not alter the low cytosolic oxidase activity in either group.
Plasma ET-1 levels. Systemic ET-1 levels in the preoperative period were significantly higher in the diabetic group (Fig. 5) . In order to examine the relationship between ET-1 levels and basal superoxide production, linear regression analysis was performed. A positive linear relationship was observed between plasma ET-1 and NAD(P)H activity with r=0.72 and p<0.001. However, incubation of specimens with a combination of ET A (BQ-123) and ET B (BQ-788) antagonists did not have an effect on basal NAD(P)H activity in either group (data not shown).
Tissue levels and translocation of NAD(P)H oxidase subunits in diabetes.
NAD(P)H oxidase consists of 2 membrane, p22phox and p91phox (nox-1 or nox-4 homologs in vascular smooth muscle cells) and 3 cytosolic subunits, p40phox, p47phox
and p67phox, which are translocated to the membrane upon activation. Therefore, tissue levels of p47phox and p67phox subunits were assayed in the cytosolic and pellet (membrane) fractions in order to determine whether ET-1 promotes translocation of these subunits and thereby activation of NAD(P)H oxidase (Fig. 6 ). The p47phox subunit was detected primarily in the cytosolic fraction and protein levels were slightly higher in the diabetic group. ET-1 stimulation increased protein levels in the cytosolic ET-1, a potent vasoactive peptide, has been shown to mediate vasoconstriction of the pulmonary and systemic circulation and influence myocardial contractility (Wenzel et al., 1998; Fleisch et al., 2000) . All these effects are relevant to patients undergoing CABG. Bond and colleagues reported that circulating ET-1 levels increase during CABG surgery in a biphasic manner (Bond et al., 2001) . Furthermore, prolonged pharmacologic management and lengthened intensive care unit are associated with elevated plasma ET-1 and increased bypass conduit sensitivity to ET-1 (Dorman et al., 2000) . However, whether and to what extent ET-1 contributes to vascular dysfunction in high-risk patients remained unknown. In light of the observations that increased ET-1 levels are associated with diabetic complications (Hattori et al., 1991) and that diabetic patients are more prone to postoperative complications (Herlitz et al., 2000) , we specifically investigated plasma ET-1 levels and ET-1-mediated graft reactivity in Griendling, 2003) . Cytoplasmic subunits (p40phox, p47phox and p67phox) are translocated to the membrane where they associate with the membrane subunits p22phox and gp91phox (or homologs nox1 and nox4) to form the active enzyme. There is recent evidence that novel homologues of p47phox (p41nox or NOXO1) and p67phox (p51nox or NOXA1) can substitute for p47phox and p67 phox (Banfi et al., 2003; Takeya et al., 2003; Griendling, 2004) . Guzik et al. demonstrated that there is enhanced production of NAD(P)H oxidase-mediated • O 2 -in the bypass conduits (both internal mammary artery and saphenous veins) obtained from patients with diabetes and this is accompanied by increased expression of the subunit proteins (Guzik et al., 2000; Guzik et al., 2002) . In contrast to our and Guzik`s findings, Huraux and colleagues reported no differences in superoxide levels or vasorelaxation in internal mammary artery segments obtained from patients with identified cardiovascular risk factors (Huraux et al., 1999) but they did not specifically investigate the effect of diabetes, which may explain the difference in their findings. Results of our current study confirm that NAD(P)H oxidase activity is significantly higher in bypass conduits obtained from diabetic patients.
Apocynin inhibits O 2
•-generation by blocking the subunit association of NADPH oxidase but if the subunit complex is already formed, it does not inhibit free radical formation.
Since basal levels were measured without any stimulation, we suspect there is significant NADPH complex already formed and that is why apocynin and DPI failed to inhibit NAD(P)H oxidase activity completely. Consistent with increased basal activity, we detected complexes of cytoplasmic and membrane subunits in the membrane fractions of vascular homogenates. We also found that plasma ET-1 levels are significantly higher in the diabetic patients and this is associated with enhanced superoxide production in diabetic patients. However, incubation of vessels with mixed ET receptor antagonists did not reduce the increased basal activity detected in the specimens • O 2 -production in both patient groups, which was more pronounced in the diabetic
group. Li et al demonstrated that ET-1 increases vascular
• O 2 -generation via NAD(P)H oxidase (Li et al., 2003) . Based on the findings by Guzik (Guzik et al., 2000; Guzik et al., 2002) and Li, we hypothesized that ET-1 induces • O 2 -production by promoting the translocation of p47phox and p67phox cytoplasmic subunits of NAD(P)H oxidase to the membrane compartment and activating the oxidase as seen by angiotensin II (Ang II) stimulation (Touyz et al., 2002) . In order to test this hypothesis, we measured oxidase activity in SV specimens stimulated with ET-1 as well as determining the protein levels of p47phox and p67phox in cytoplasmic and membrane fractions prepared from bypass conduits stimulated with ET-1. To our surprise, there was no change in NAD(P)H oxidase activity in ET-1-stimulated tissue in either the diabetic or nondiabetic group. ET-1-stimulation also failed to cause a shift of p47phox and p67phox from the cytoplasm to membrane. In light of the recent evidence that NOXO1 and NOXA1 can substitute for p47phox and p67phox, respectively, one possibility is that ET-1 may stimulate these novel homologues and not conventional cytoplasmic subunits of NAD(P)H oxidase. Due to lack of specific antibodies for these homologues, we could not investigate this Limitations of this study must be recognized. All patients had coronary artery disease. Although vascular tissue specimens used in this study were considered relatively healthy and utilized for bypass conduits, we cannot differentiate the impact of coronary artery disease on these ROS-generating systems in our study population.
This article has not been copyedited and formatted. The final version may differ from this version. Second, we only evaluated saphenous vein conduits since the amount of internal mammary artery, another commonly used bypass conduit, is quite limited. Third, all the patients were receiving pharmacotherapy for comorbid conditions. Although medications, age and comorbid conditions appear to be similar in both groups, in the diabetes group there were more African American patients and the number of subjects in each group is small for multivariate analyses. Complex drug interactions, ethnic differences and effects of concurrent diseases on oxidative stress markers remain potential confounding factors. Nevertheless, the findings of this study demonstrate that ET-1 alters bypass conduit reactivity in part by stimulating excess formation of ROS in diabetes. This study also provides novel evidence that ET-1 induces • O 2 -via a non-NAD(P)H dependent mechanism in the venous grafts. While acute modulation of the tone of bypass graft conduits by
• O 2 -may be critical for the pharmacological management of postoperative vasospasm, long-term consequences may be increased proliferative response to vascular injury as shown in an experimental venous bypass grafts (West et al., 2001) . Since the long-term results of CABG are limited by stenosis and subsequent occlusion of SV grafts, the most commonly utilized conduit for these operative procedures (Angelini and Newby, 1989; Cox et al., 1991; Bryan and Angelini, 1994; Davies and Hagen, 1995; Davies et al., 1998) , ET receptor antagonism may offer a therapeutic benefit especially in high-risk diabetic patients.
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